EC Microbiology

Guest Editorial Volume 19 Issue 6 - 2023

TB-Whole Genome Sequencing Bridging the Diagnostic Gaps for Effective Treatment

Rajendra Prasad1* and Aparna Bhanushali2

1Director Medical Education and Professor, Pulmonary Medicine, Era’s Lucknow Medical College and Hospital, Era University Lucknow, India

2Head-Growth and Scientific Support, Haystack Analytics Pvt Ltd, Society for Innovation and Entrepreneurship, Indian Institute of Technology-Mumbai, India

*Corresponding Author: Rajendra Prasad, Director Medical Education and Professor, Pulmonary Medicine, Era’s Lucknow Medical College and Hospital, Era University Lucknow, India.
Received: June 01, 2023; Published: June 22, 2023

Keywords: Tuberculosis; Whole Genome Sequencing; Multi-Drug Resistant TB; End TB


TB: Tuberculosis; WGS: Whole Genome Sequencing; WHO: World Health Organization; MDR-TB: Multidrug Resistant TB; XDR-TB: Extremely Drug-Resistant; PMDT: Programmatic Management of Drug-Resistant TB; DST: Drug-Sensitivity Test; CDST: Culture-Drug Sensitivity; RR: Rifampicin Resistance; RRDR: Rifampicin Resistance Defining Region; NGS: Next Generation Sequencing; PZA: Pyrazinamide; INH: Isoniazid; RIF: Rifampicin; MIC: Minimum Inhibitory Concentration; MGIT: Mycobacterial Growth Indicator Tube; TA: Turn-Around-Time


Tuberculosis (TB) affects millions every year, causing great morbidity and mortality worldwide (approximately 1.4 million lives in 2021) [1]. Despite being preventable and curable, TB still remains a major challenge to public health, with a large number of patients failing to respond to standard treatment. TB dramatically affects the quality-of-life of the patients, and also raises many socio-economic issues especially in medium- and high-burden regions like India, Pakistan, China, Indonesia.

  1. Global tuberculosis report (2022).
  2. Global tuberculosis report.
  3. Zade A., et al. “Whole-genome sequencing of presumptive MDR-TB isolates from a tertiary healthcare setting in Mumbai”. Journal of Global Antimicrobial Resistance 31 (2022): 256-262.
  4. Nyugen TNA., et al. “Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review”. Frontiers in Microbiology 10 (2019): 794.
  5. Jiang J., et al. “Head-to-head comparison of the diagnostic accuracy of Xpert MTB/RIF and Xpert MTB/RIF Ultra for tuberculosis: a meta-analysis”. Infectious Diseases11 (2020): 763-775.
  6. Zhang M., et al. “Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: A preliminary systematic review and meta-analysis”. International Journal of Infectious Diseases 90 (2020): 35-45.
  7. Wang L., et al. “Whole-genome sequencing of Mycobacterium tuberculosis for prediction of drug resistance”. Epidemiology and InfectionE22 (2022): 1-8.
  8. He G., et al. “Prediction of treatment outcomes for multidrug-resistant tuberculosis by whole-genome sequencing”. International Journal of Infectious Diseases 96 (2020): 68-72.
  9. Advani J., et al. “Whole Genome Sequencing of Mycobacterium tuberculosis Clinical Isolates From India Reveals Genetic Heterogeneity and Region-Specific Variations That Might Affect Drug Susceptibility”. Frontiers in Microbiology 10 (2019): 309.
  10. Katale BZ., et al. “Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania”. BMC Genomics 21 (2020): 174.
  11. Lin WH., et al. “Disputed rpoB mutations in Mycobacterium tuberculosis and tuberculosis treatment outcomes”. Antimicrobial Agents and Chemotherapy 65 (2021): e01573-20.
  12. Miotto P., et al. “Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis”. Journal of Clinical Microbiology5 (2018): e01599-17.

Rajendra Prasad and Aparna Bhanushali. “TB-Whole Genome Sequencing Bridging the Diagnostic Gaps for Effective Treatment”. EC Microbiology  19.6 (2023): 01-03.